Inventiva S.A. IVA
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- -21.51%
- 1 year
- -12.05%
- Open
- 3.69
- Prev close
- 3.73
- Mkt cap
- 862.21M
- Vol
- 1.73M
- Avg vol
- 1.92M
- EPS
- -0.62
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 3.59
- High
- 3.76
- Forward P/E
- -5.34
- Beta
- 0.92
- Short ratio
- 3.38
- Inst. own
- 41.80%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Sep 25, 2026
- 50-d avg
- 4.53
- 200-d avg
- 5.07
- 1y target
- 14.62
News
2 weeks ago seekingalpha.com
Inventiva: Significant Upside Potential Ahead Of Pivotal Liver Disease Readout
Inventiva receives a speculative strong buy rating, with a probability-weighted fair value of ~$15 per share versus ~$3.20 currently. Following strong Phase 2b NATIVE results, lanifibranor's pivotal…
2 weeks ago defenseworld.net
Inventiva (NASDAQ:IVA) Sets New 12-Month Low – Here’s What Happened
Shares of Inventiva S.A. Sponsored ADR (NASDAQ: IVA - Get Free Report) reached a new 52-week low on Tuesday. The company traded as low as $3.10 and last traded at $3.12, with a volume of 3,264,826…
3 weeks ago marketbeat.com
3 Beaten-Down Biotech Stocks With Triple-Digit Upside and Big Catalysts Ahead
Small-cap stocks tend to fly under the radar. Often in startup stages, these companies can lack analyst coverage, be overlooked by institutional investors, and be illiquid due to low average trading…
3 weeks ago gurufocus.com
Vertex to Present New Data on ALYFTREK® at the North American Cystic Fibrosis Conference
[url="]Vertex Pharmaceuticals Incorporated[/url] (Nasdaq: VRTX) today announced new interim data from the ALYFTREKÂ (vanzacaftor/tezacaftor/deutivacaftor) 2 to
4 weeks ago marketbeat.com
Inventiva Eyes Q4 2026 Phase III MASH Data as Lanifibranor Nears Key Test
Inventiva NASDAQ: IVA said it expects to report top-line results in the fourth quarter of 2026 from its fully enrolled Phase III NATiV3 trial of lanifibranor in patients with metabolic…
4 weeks ago defenseworld.net
Inventiva (NASDAQ:IVA) Shares Gap Down – Here’s Why
Inventiva S.A. Sponsored ADR (NASDAQ: IVA - Get Free Report)'s share price gapped down before the market opened on Thursday. The stock had previously closed at $3.69, but opened at $3.38. Inventiva…
-
1 month ago benzinga.com
Truist Securities Maintains Buy on Inventiva, Raises Price Target to $18
Truist Securities analyst Srikripa Devarakonda maintains Inventiva (NASDAQ:IVA) with a Buy and raises the price target from $13 to $18.
1 month ago defenseworld.net
Inventiva (NASDAQ:IVA) Shares Gap Up – Here’s What Happened
Inventiva S.A. Sponsored ADR (NASDAQ: IVA - Get Free Report) shares gapped up prior to trading on Wednesday. The stock had previously closed at $3.29, but opened at $3.51. Inventiva shares last…
1 month ago benzinga.com
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Gainers DataMEDS AI (NASDAQ:MEDS) stock moved upwards by 39.4% to $4.42 during Thursday's pre-market session. The company's market cap stands at $10.1 million. Stablecoin Development (AMEX:SDEV)…
1 month ago benzinga.com
Progress Software, Nft And Other Big Stocks Moving Lower In Thursday’s Pre-Market Session
U.S. stock futures were mixed as Progress Software fell after results; Corteva, NFT, Vivakor and other stocks also dropped in premarket trading.
1 month ago defenseworld.net
Inventiva S.A. Sponsored ADR (NASDAQ:IVA) Stock Has Consensus Price Target of $15.14
Inventiva S.A. Sponsored ADR (NASDAQ: IVA - Get Free Report) has earned a consensus rating of "Buy" from the ten analysts that are presently covering the stock, MarketBeat reports. One research…
1 month ago benzinga.com
Why Vicor Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
Vicor shares surged 12% after raising Q3 growth guidance above 30%; Roze AI led gainers, while Corteva plunged 57% premarket.
1 month ago benzinga.com
Hewlett Packard Enterprise, Capital Bancorp, FormFactor And Other Big Stocks Moving Higher On Wednesday
U.S. stocks rose as Nasdaq gained 100+ points; HPE jumped 5.1% on stronger networking guidance and a Vultr AI rack order.
1 month ago defenseworld.net
Inventiva (NASDAQ:IVA) Stock Price Up 5.5% – Time to Buy?
Inventiva S.A. Sponsored ADR (NASDAQ: IVA - Get Free Report) shares rose 5.5% on Monday. The stock traded as high as $3.56 and last traded at $3.5540. Approximately 1,594,845 shares traded hands…
-
1 month ago benzinga.com
Canaccord Genuity Maintains Buy on Inventiva, Raises Price Target to $21
Canaccord Genuity analyst Edward Nash maintains Inventiva (NASDAQ:IVA) with a Buy and raises the price target from $20 to $21.
1 month ago benzinga.com
Vail Resorts, Inventiva And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures were mixed this morning, with the Dow futures falling around 0.1% on Tuesday.
1 month ago benzinga.com
Vail Resorts, Inventiva And Other Big Stocks Moving Lower In Tuesday’s Pre-Market Session
U.S. futures mixed as Vail Resorts fell after a Q4 loss miss despite beating sales estimates; several stocks also declined premarket.
1 month ago seekingalpha.com
Inventiva S.A. (IVA) Q2 2026 Earnings Call Transcript
Inventiva S.A. (IVA) Q2 2026 Earnings Call Transcript
1 month ago marketbeat.com
Inventiva Q2 Earnings Call Highlights
Inventiva NASDAQ: IVA said it remains on track to report top-line results from its Phase III NATiV3 trial of lanifibranor in metabolic dysfunction-associated steatohepatitis, or MASH, in the fourth…
1 month ago defenseworld.net
Inventiva Q2 Earnings Call Highlights
Inventiva (NASDAQ: IVA) said it remains on track to report top-line results from its Phase III NATiV3 trial of lanifibranor in metabolic dysfunction-associated steatohepatitis, or MASH, in the fourth…
-
1 month ago benzinga.com
Inventiva H1 2026 Earnings Call: Complete Transcript
On Monday, Inventiva (NASDAQ:IVA) discussed quarterly financial results during its earnings call. The full transcript is provided below. This content is powered by Benzinga APIs. For comprehensive…
1 month ago benzinga.com
Earnings Scheduled For September 28, 2026
Companies Reporting Before The Bell • Kandi Technologies Gr (NASDAQ:KNDI) is likely to report earnings for its first quarter. • Inventiva (NASDAQ:IVA) is expected to report quarterly loss at $0.20…
-
1 month ago benzinga.com
Inventiva H1 EPS $(0.29) Misses $(0.20) Estimate, Sales $23.251K Miss $10.000M Estimate
Inventiva (NASDAQ:IVA) reported quarterly losses of $(0.29) per share which missed the analyst consensus estimate of $(0.20) by 45 percent. This is a 84.24 percent increase over losses of $(1.84) per…
1 month ago globenewswire.com
Inventiva Reports Unaudited 2026 First-Half Financial Results and Provides Corporate Update
Daix (France), New York (New York, United States), September 28, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA ) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused…
-
1 month ago benzinga.com
Earnings Scheduled For September 25, 2026
Companies Reporting Before The Bell • Tamboran Resources (NYSE:TBN) is estimated to report quarterly loss at $0.30 per share on revenue of $3.82 million. Companies Reporting After The Bell •…
1 month ago benzinga.com
Novo Nordisk, Telix Pharmaceuticals And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. futures rose, but Novo Nordisk fell 4.8% after Cagrisema trial results; Aligos, Telix and other stocks also dropped premarket.
1 month ago seekingalpha.com
Inventiva S.A. (IVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Inventiva S.A. (IVA) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
-
1 month ago benzinga.com
Guggenheim Maintains Buy on Inventiva, Raises Price Target to $14
Guggenheim analyst Seamus Fernandez maintains Inventiva (NASDAQ:IVA) with a Buy and raises the price target from $11 to $14.
1 month ago globenewswire.com
Inventiva to Present Multiple Abstracts at Paris MASH 2026
Daix (France), New York (New York, United States), September 8, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on…
1 month ago globenewswire.com
RUBIS: H1 2026 Results - Strong performance leading way to upgrade of 2026 guidance
Paris, 08 September 2026, 7:00am EBITDA at €434m, +18% yoy reflecting sustained demand, disciplined execution and optimised inventory management in a volatile and high oil price context, highlighting…
-
2 months ago benzinga.com
Inventiva Completes Final 72-Week NATiV3 Patient Visit With 1,419 Patients Enrolled, Topline Results Expected Q4 2026
Last patient completed final 72-week visit in NATiV3, with 1,009 patients enrolled in the main cohort and 410 patients in the exploratory cohortTopline results of NATiV3 expected in Q4 2026September…
2 months ago globenewswire.com
Inventiva Announces Last Patient Visit in NATiV3 Phase 3 Clinical Trial of Lanifibranor in MASH
Daix (France), New York (New York, United States), September 2nd, 2026 – Inventiva (Euronext Paris and Nasdaq: IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused…
2 months ago benzinga.com
12 Health Care Stocks Moving In Tuesday's After-Market Session
Gainers Intelligent Bio Solutions (NASDAQ:INBS) stock moved upwards by 8.2% to $2.63 during Tuesday's after-market session. The company's market cap stands at $7.2 million. Jaguar Health…
2 months ago globenewswire.com
Inventiva Appoints Chris Benecchi as Chief Operating Officer
Daix (France), New York City (New York, United States), August 31, 2026 – Inventiva (Euronext Paris and NASDAQ: IVA) (“Inventiva” or the “Company”), a clinical-stage biopharmaceutical company focused…
2 months ago benzinga.com
Pinterest, Destiny Tech100 And Other Big Stocks Moving Lower In Monday’s Pre-Market Session
U.S. stock futures were lower this morning, with the Dow futures falling around 0.2% on Monday. Shares of Pinterest, Inc. (NYSE:PINS) fell sharply in pre-market trading following the announcement…
2 months ago seekingalpha.com
Inventiva: MASH Is Becoming A Combination Market Before Lanifibranor Arrives
Inventiva is positioned as a high-risk, clinical catalyst play targeting MASH with its oral pan-PPAR agonist, lanifibranor. Lanifibranor's potential lies in combination therapy, offering dual…
-
3 months ago benzinga.com
Inventiva Reports No Revenue During H1, Compared To €4.5M YoY
Inventiva (Euronext Paris and NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of an oral therapy for the treatment of metabolic
3 months ago benzinga.com
Kura Sushi Posts Weak Q3 Sales, Joins FuelCell Energy And Other Big Stocks Moving Lower In Wednesday’s Pre-Market Session
US stock futures lower with Dow down 500 points. Kura Sushi shares drop after reporting worse-than-expected sales. Other stocks also decline in pre-market.
-
4 months ago benzinga.com
Inventiva Secures €43M Investment for Liver Disease Drug, Supports Phase 3 MASH Treatment Trial
Europe's largest independent growth debt fund manager has made an investment through its funds, of €43m in Inventiva (NASDAQ:IVA), a clinical-stage biopharmaceutical company developing an oral…
4 months ago benzinga.com
Super Micro Computer, Summit Therapeutics And Other Big Stocks Moving Lower In Wednesday's Pre-Market Session
US stock futures lower, Nasdaq down 1%. Super Micro shares down 8.6% after announcing $7B offering to fund AI orders. Other stocks also down in pre-market trading.
-
5 months ago benzinga.com
Inventiva Enters Comprehensive Refinancing Agreements, Comprising Repayment Of The Existing EIB Loan And Partial Warrant Buyback Of Those Issued The EIB; Shares Resume Rrading On Euronext Paris
Secured a new debt financing with funds and accounts managed by BlackRock and Claret Capital Partners, respectively for up to €130 million in committed tranches, subject to conditions, plus an…
-
5 months ago benzinga.com
Inventiva Halts Paris Trading Ahead of Planned Financing Announcement, Shares Expected to Resume Trading Later Tuesday
Inventiva (NASDAQ:IVA) ("Inventiva" or the "Company"), a clinical-stage biopharmaceutical company focused on the development of oral therapies for the treatment of metabolic dysfunction-associated…
7 months ago benzinga.com
Phreesia, Service Properties Trust, Inventiva And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session
U.S. stock futures rise on Tuesday with Dow futures up 400 points. Phreesia shares fall 26.5% in pre-market after mixed Q4 results and lower sales guidance. Other stocks also decline.
7 months ago benzinga.com
Why Virgin Galactic Shares Are Trading Higher By 6%; Here Are 20 Stocks Moving Premarket
Virgin Galactic reported Q4 revenue of $312,000, missing estimates, but beat EPS expectations. Its second SpaceShip is expected to enter service soon, causing a 6% jump in pre-market trading. Other…
-
7 months ago benzinga.com
Inventiva FY EPS $(2.14) Misses $(1.66) Estimate, Sales $5.064M Miss $6.000M Estimate
Inventiva (NASDAQ:IVA) reported quarterly losses of $(2.14) per share which missed the analyst consensus estimate of $(1.66) by 28.92 percent. This is a 35.74 percent increase over losses of $(3.33)…
-
7 months ago benzinga.com
Earnings Scheduled For March 30, 2026
Earnings Scheduled For March 30, 2026
7 months ago benzinga.com
Zenas Biopharma, Daqo New Energy And Other Big Stocks Moving Lower In Friday's Pre-Market Session
U.S. stock futures down, Zenas Biopharma shares fall 9.5% in pre-market trading due to pricing of public offerings. Other stocks also lower.
7 months ago benzinga.com
Why Newsmax Shares Are Trading Higher By Around 5%; Here Are 20 Stocks Moving Premarket
Newsmax Inc (NMAX) shares rose on better-than-expected Q4 results & FY26 sales guidance. Pre-market gainers include ONCO, VSA, GMEX, IZM, GVH, BATL, U, SGML, & GLND. Losers are SLND, DTCX, TOP, SVRN,…
7 months ago benzinga.com
This Rocket Lab Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
Wall Street analysts changed outlook on top names. Clear Street initiated coverage on RKLB with Buy rating, $88 PT. See analyst ratings.
-
7 months ago benzinga.com
Truist Securities Initiates Coverage On Inventiva with Buy Rating, Announces Price Target of $13
Truist Securities analyst Srikripa Devarakonda initiates coverage on Inventiva (NASDAQ:IVA) with a Buy rating and announces Price Target of $13.